Understanding how C. difficile toxins affect the gut
Gastrointestinal cell type-specific signaling and C. difficile toxin pathogenesis
This study is looking at how a harmful germ called C. difficile affects the gut and how our bodies react to it, especially focusing on a specific toxin that causes problems, to find better ways to treat and prevent infections for people who keep getting sick.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10948083 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which C. difficile toxins damage colonic tissue and how the human body responds to these toxins. It focuses on the role of toxin B, a key factor in C. difficile infections, and aims to identify new therapeutic targets to prevent and treat these infections. By studying the interactions between the toxins and host cells, the research seeks to improve treatment strategies, particularly for patients suffering from recurrent infections. The approach includes examining the signaling pathways involved in the disease process and exploring potential new therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients who have experienced recurrent C. difficile infections or are at high risk for these infections, particularly those with a history of antibiotic use.
Not a fit: Patients who have not been diagnosed with C. difficile infections or those who do not have a history of antibiotic-associated diarrhea may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from C. difficile infections, reducing the incidence of recurrent and drug-resistant cases.
How similar studies have performed: Previous research has shown promising results in understanding the pathogenesis of C. difficile and the effectiveness of therapies targeting its toxins, indicating that this approach has potential for success.
Where this research is happening
Nashville, United States
- Veterans Health Administration — Nashville, United States (Active)
Researchers
- Principal investigator: Markham, Nicholas O — Veterans Health Administration
- Study coordinator: Markham, Nicholas O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.